Healthcare companies including InBody, Meju and D&D Pharmatech make a series of announcements, 5Month 27~28day

5Month 27day and 28day saw a series of disclosures and announcements in South Korea’s biotech and healthcare industries. The companies involved included InBody, Meju, D&D Pharmatech, Daewoong, Seers, TR and Deepnoid. The announcements covered collaboration, manufacturing approval, share-price movements and research publication.

InBody 5Month 28day announced a collaboration with Naver Healthcare to provide an AI-based body composition management service. The company said demand for body composition analysis is increasing as the obesity-management market expands. InBody’s announcement focused on service integration and data use.

Meju 5Month 28day disclosed that it had received manufacturing approval for a next-generation product. The company said expectations for improved results had formed on the basis of the approval. Meju shares surged following the news.

DND Pharmatech 5 month 27 day, its stock hit the upper price limit. The company notified the market of the situation in a related disclosure. The limit-up was immediately reflected in the investment market.

Daewoong, Seers Technology, and TR 5 month 28 day, announced that they would jointly develop a next-generation smart hospital ward solution. The three companies disclosed that they had formed an alliance to cooperate on developing the solution. The disclosure focused on plans for joint research and commercialization.

Deepnoid 5 month 28 day, announced that its AI research in colon pathology had been published in an academic journal. The company said it would continue to provide the related solution. The announcement focused on the research achievement and continued product supply.